Shopping Cart (0)
My Account

 Shopping Cart
Conferences | Training Courses | Market Reports | Managed Events | Past Conferences | Update Me
SELECTBIO Conferences Circulating Biomarkers World Congress 2016
Conferences  \  Circulating Biomarkers World Congress 2016  \  Agenda  \  Phil Stephens
RegisterLogin

Phil Stephens's Biography


Phil Stephens, Chief Scientific Officer, Foundation Medicine

Dr. Stephens leads research and development at Foundation Medicine. Dr. Stephens is a world-renowned expert in next-generation sequencing and cancer genome analysis and has authored numerous publications in Nature, Nature Genetics, Nature Medicine, Cell and other high-profile journals. Since joining Foundation Medicine in early 2011 Dr Stephens has overseen the development of FoundationOne™, and FoundationOne™ Heme, comprehensive next generation sequencing diagnostic assays that accurately profiles the entire coding sequence of hundreds of cancer-related genes in the CLIA setting. Prior to joining Foundation Medicine, Dr. Stephens held various senior research positions during his 11-year tenure with the Cancer Genome Project at the Wellcome Trust Sanger Institute under the direction of Sir Professor Michael Stratton.

Phil Stephens Image

Will the Liquid Biopsy End FFPE Biopsy Testing to Guide Therapeutic Decisions for Patients with Cancer?

Monday, 21 March 2016 at 11:30

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

There is tremendous excitement about the potential of “the liquid biopsy” to identify targeted therapeutic options for patients with cancer. However, for many tumor types,  significant and likely insurmountable challenges exist that currently exclude the liquid biopsy as an appropriate diagnostic specimen. This seminar will give a comprehensive overview of the complexities physician’s face in selecting the appropriate diagnostic assay to maximize treatment options for their patients.

Will the Liquid Biopsy End FFPE Biopsy Testing to Guide Therapeutic Decisions for Patients with Cancer?

Monday, 21 March 2016 at 11:30

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

There is tremendous excitement about the potential of “the liquid biopsy” to identify targeted therapeutic options for patients with cancer. However, for many tumor types,  significant and likely insurmountable challenges exist that currently exclude the liquid biopsy as an appropriate diagnostic specimen. This seminar will give a comprehensive overview of the complexities physician’s face in selecting the appropriate diagnostic assay to maximize treatment options for their patients.

Will the Liquid Biopsy End FFPE Biopsy Testing to Guide Therapeutic Decisions for Patients with Cancer?

Monday, 21 March 2016 at 11:30

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

There is tremendous excitement about the potential of “the liquid biopsy” to identify targeted therapeutic options for patients with cancer. However, for many tumor types,  significant and likely insurmountable challenges exist that currently exclude the liquid biopsy as an appropriate diagnostic specimen. This seminar will give a comprehensive overview of the complexities physician’s face in selecting the appropriate diagnostic assay to maximize treatment options for their patients.

Add to Calendar ▼2016-03-21 00:00:002016-03-22 00:00:00Europe/LondonCirculating Biomarkers World Congress 2016Circulating Biomarkers World Congress 2016 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com


Corporate Sponsors